|
|
|
Upcoming Webinar:
"Genetically diverse HIV-1 vaccines for prevention and the cure"
|
|
Please join us for a webinar entitled “Genetically Diverse HIV-1 Vaccines for Prevention and the Cure” presented by Dr. Eric J. Arts, Chair of the Department of Microbiology and Immunology at Western University in London, Canada. This webinar will provide Canadian researchers and members of the Canadian HIV Vaccine Initiative Research and Development Alliance with a greater understanding of the different strains of HIV-1 virus that cause differences in disease development and progression. This webinar will also include a discussion about possibilities for how HIV/AIDS can be treated and potentially cured.
|
|
Presenter: Dr. Eric J. Arts, Chair of the Department of Microbiology and Immunology, Western University, London, Canada
Date: Wednesday, August 26, 2015
Time: 2:00-3:00 PM EDT (1:00-2:00 PM CDT, 12:00 PM – 1:00 PM MDT and 11:00 AM – 12:00 PM PDT)
Download the webinar poster
Want to Know What the ACO has Been Up To?
|
|
Featured Videos: CAHR 2015 Vaccine Scholars
The ACO was pleased to partner with the Canadian Association for HIV Research (CAHR) to offer eight academic scholarships in vaccine research at the CAHR 2015 Conference. The scholarships are awarded based purely on scientific merit. The following two award recipients presented their research at the conference:
|
|
Luca Melnychuk is a master’s student at McGill University. His research team aims to develop an adjuvant that will help in the design of an HIV vaccine by increasing the immune response and induce a broadly neutralizing antibody in humans. WATCH THE VIDEO
|
|
Natalie Kinloch is a new investigator at Simon Fraser University whose research focuses on immune mediated adaptation in HIV, specifically the impact of HLA mediated immune selection pressure. Her study looks at the accumulation of HLA associated polymorphisms over the course of the epidemic in North America. WATCH THE VIDEO
|
|
New Research
|
|
A critical analysis of the cynomolgus macaque, Macaca fascicularis, as a model to test HIV-1/SIV vaccine efficacy.
Antony JM, MacDonald KS
Vaccine. 2015 Jun 17;33(27):3073-3083. doi: 10.1016/j.vaccine.2014.12.004. Epub 2014 Dec 12.
The use of a number of non-rhesus macaque species, but especially cynomolgus macaques as a model for HIV-1 vaccine development has increased in recent years. Cynomolgus macaques have been used in the United Kingdom, Europe, Canada and Australia as a model for HIV vaccine development for many years. Unlike rhesus macaques, cynomolgus macaques infected with SIV show a pattern of disease pathogenesis that more closely resembles that of human HIV-1 infection, exhibiting lower peak and set-point viral loads and slower progression to disease with more typical AIDS defining illnesses. Several advances have been made recently in the use of the cynomolgus macaque SIV challenge model that allow the demonstration of vaccine efficacy using attenuated viruses and vectors that are both viral and non-viral in origin. This review aims to probe the details of various vaccination trials carried out in cynomolgus macaques in the context of our modern understanding of the highly diverse immunogenetics of this species with a view to understanding the species-specific immune correlates of protection and the efficacy of vectors that have been used to design vaccines. READ MORE.
Protective efficacy of adenovirus-protein vaccines against SIV challenges in rhesus monkeys
Barouch DH, Alter G, Broge T, et al.
Science aab3886Published online 2 July 2015 [DOI:10.1126/science.aab3886]
Preclinical studies of viral vector–based HIV-1 vaccine candidates have previously shown partial protection against neutralization-resistant virus challenges in rhesus monkeys. In this study, we evaluated the protective efficacy of adenovirus serotype 26 (Ad26) vector priming followed by purified envelope (Env) glycoprotein boosting. Rhesus monkeys primed with Ad26 vectors expressing SIVsmE543 Env, Gag, and Pol and boosted with AS01B-adjuvanted SIVmac32H Env gp140 demonstrated complete protection in 50% of vaccinated animals against a series of repeated, heterologous, intrarectal SIVmac251 challenges that infected all controls. Protective efficacy correlated with the functionality of Env-specific antibody responses. Comparable protection was also observed with a similar Ad/Env vaccine against repeated, heterologous, intrarectal SHIV-SF162P3 challenges. These data demonstrate robust protection by Ad/Env vaccines against acquisition of neutralization-resistant virus challenges in rhesus monkeys. READ MORE.
HIV and mucosal barrier interactions: consequences for transmission and pathogenesis
Burgener A, McGowan I, Klatt NR
Curr Opin Immunol. 2015 Jul 4;36:22-30. doi: 10.1016/j.coi.2015.06.004. [Epub ahead of print]
The mucosal barrier plays an integral function in human health as it is the primary defense against pathogens, and provides a critical transition between the external environment and the human internal body. In the context of HIV infection, the most relevant mucosal surfaces include those of the gastrointestinal (GI) and genital tract compartments. Several components help maintain the effectiveness of this mucosal surface, including the physical anatomy of the barrier, cellular immunity, soluble factors, and interactions between the epithelial barrier and the local microenvironment, including mucus and host microbiota. Any defects in barrier integrity or function can rapidly lead to an increase in acquisition risk, or with established infection may result in increased pathogenesis, morbidities, or mortality. Indeed, a key feature to all aspects of HIV infection from transmission to pathogenesis is disruption and/or dysfunction of mucosal barriers. Herein, we will detail the host-pathogen relationship of HIV and mucosal barriers in both of these scenarios. READ MORE.
|
|
Resources
Canadian HIV Vaccine Initiative (CHVI) Interactive Projects Map
The CHVI's Interactive Projects Map highlights recipients of CHVI funding around the world and visual guide to some of Canada's contribution to HIV/AIDS research. TRY THE MAP to find out where Canadian HIV vaccine research is taking place.
|
|
Funding Opportunities
Canadian Institutes of Health Research
Doctoral Research Award: Vanier Canada Graduate Scholarships (2015-2016)
Application Deadline: 2015-11-04
LEARN MORE
Fellowship: 2015 – 2016
Application Deadline: 2015-11-02
LEARN MORE
Banting Postdoctoral Fellowships Program 2015 – 2016
Application Deadline: 2015-09-23
LEARN MORE
New Investigator Salary Award: 2015 – 2016
Application Deadline: 2015-12-01
LEARN MORE
New Investigator Salary Award: Winter 2015 Priority Announcement
Application Deadline: 2015-12-01
LEARN MORE
|
|
Conferences
|
|
September 10 to 13, 2015
US Conference on AIDS
Washington, DC
|
|
September 13 to 16, 2015
World STI & HIV 2015 Congress
Brisbane, Australia
|
|
October 21-24, 2015
15th European AIDS Conference
Barcelona, Spain
|
|
November 29 to December 4, 2015
International Conference on AIDS & STI in Africa (ICASA)
Harare, Zimbabwe
|
|
November 30 to December 2, 2015
3rd International Conference on HIV/AIDS, STDs & STIs
Atlanta, USA
|
|
February 22 to 25 2016
Conference on Retroviruses and Opportunistic Infections (CROI) 2016
Boston, USA
|
|
March 20 to 24, 2016
Keystone Symposia – HIV Persistence: Pathogenesis and Eradication (X7)
California, USA
|
|
March 20 to 24, 2016
Keystone Symposia – HIV Vaccines (X8)
California, USA
|
|
May 12 to 15 2016
CAHR 2016
Winnipeg, Canada
|
|
→
See full list of conferences
|
|
| |
| |
| |
| |
|
You are receiving this email because you registered to receive news updates from the Canadian HIV Vaccine Initiative (CHVI) Research and
Development Alliance Coordinating Office
or you are a member of a CHVI-funded
project team.
|
| |
|
Follow Us:
|
|
|
| |
| |
|
Address
|
|
ALLIANCE COORDINATING OFFICE
International Centre for Infectious Diseases
515 Portage Avenue
Winnipeg, MB, Canada
R3B 2E9
Tel.: 204 946 0908
Fax: 204 946 0927
email:
aco@icid.com
|
|
| |
| |
|
About Us
|
|
The CHVI Research and Development Alliance Coordinating Office (ACO) was established by the Government of Canada and the Bill & Melinda Gates Foundation in November 2011 at the International Centre for Infectious Diseases (ICID), a
not-for-profit,
non-governmental organization based in Winnipeg.
|
|
| |
|
White Paper
|
The ACO has developed a White Paper to foster effective coordination of key players across the Canadian HIV vaccine research landscape.
|
|
Read more
|
|
|
